CureVac NV’s candidate messenger RNA (mRNA) vaccine against Covid-19 has shown an overall efficacy rate of 48% in a large Phase 2b/3 trial during which multiple new strains of the SARS-CoV-2 virus were in circulation. The efficacy rate was achieved against Covid-19 disease of any severity, including single non-respiratory mild symptoms, the developer announced on 30 June.
